The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
And well-established in the UK
https://oneashfield.com/
And, perhaps, the star of the show, Prof Sir Stephen Holgate, has, as far as I’m aware made no public comment since receiving his knighthood.
But still pursuing his long held agenda against air pollution.
Cool dude.
;-)
On reflection, the FDA’s CRL letter must have been a MASSIVE shock to the company.
While I have a lot of respect for Hullihen and his team, a 12 mth delay to approval (for such a breakthrough product) will seem like a lifetime.
Tough times.
Markets don’t like uncertainty - and that’s what we have here. So, although volume traded is very low, a few ‘sells’ or ‘buys’(who knows which is which with such an unhelpful spread) will shift the sp noticeably one way or another.
I guess there’s nothing the company can say at the moment as they don’t control the newsflow.
So we wait….
Maybe, but likely not AZN who are getting out of the COPD market:
https://www.pharmaceutical-technology.com/news/covis-pharma-acquire-astrazeneca-medicines/?utm_source=Army%20Technology&utm_medium=website&utm_campaign=Must%20Read&utm_content=Image